An interventional study of Rifaximin in Intestinal FDG Uptake, sponsored by Beth Israel Deaconess Medical Center. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-12-13.
Sponsored by Beth Israel Deaconess Medical Center · Not applicable, Interventional, and Diagnostic
Patients who undergo PET-CT scans to look for cancer are given an intravenous contrast (FDG) that is taken-up by active cells such as cancer cells. This contrast can then be seen in the body using the PET-CT scanner. However, cells in the colon also take up the FDG, and can produce "false positive" signals from the colon. Our hypothesis is that much of this signal comes from bacteria that are present in high concentrations in the colon. If this is the case, using an antibiotic to suppress the activity of bacteria may improve the ability of PET-CT to distinguish abnormal cells from normal cells in the colon.
Beth Israel Deaconess Medical Center is the lead sponsor of 560 studies on the registry; 80 are open to participants now.
Of its 75 completed or terminated interventional studies of FDA-regulated products, 61 (81%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: Rifaximin
Randomly-selected matched PET-CT scans performed on same day as intervention group.
550mg BID for 2 days
Also known as: Xifaxan
SUVmax of FDG in Each Colonic Segment
Time frame: Day 2
SUVavg in Each Colonic Segment
Time frame: Day 2
| Milestone | Rifaximin | Control |
|---|---|---|
| Started | 38 | 30 |
| Completed | 30 | 30 |
| Not completed | 8 | 0 |
| SUV | Rifaximin | Control |
|---|---|---|
| SUVmax of FDG in Each Colonic Segment | 4.6 ± 2.3 | 4.3 ± 2.7 |
| SUV | Rifaximin | Control |
|---|---|---|
| SUVavg in Each Colonic Segment | 1.6 ± 0.9 | 1.8 ± 0.9 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rifaximin | — | 0/30 (0%) | 0/30 (0%) |
| Control | — | 0/30 (0%) | 0/30 (0%) |
| Age, Continuous(years) | Rifaximin | Control | Total |
|---|---|---|---|
| Mean | 56 ± 19 | 56 ± 19 | 56 ± 19 |
| Sex: Female, Male(Participants) | Rifaximin | Control | Total |
|---|---|---|---|
| Female | 17 | 15 | 32 |
| Male | 21 | 15 | 36 |
| Region of Enrollment(participants) | Rifaximin | Control | Total |
|---|---|---|---|
| United States | 38 | 30 | 68 |
This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Beth Israel Deaconess Medical Center